Siemens 2024
Siemens Innovations for Healthcare Professionals
Booth 2 | Orlando, FL | May 21-23, 2024
Discover the ProFound Breast AI Health Suite
Together, we can change more lives.
Backed by science, clinical evidence, and proven patient outcomes, our suite of solutions – Detection, Density, and Risk – shine a spotlight on cancer, exposing its hiding place. Empowering you to personalize breast cancer screening like never before.
Cancer wins when it hides.
When it comes to cancer, hide and seek is no game.
iCAD is creating a world where cancer can’t hide with innovative artificial intelligence solutions that empower providers and professionals to accurately, reliably and quickly detect cancer and improve outcomes – optimizing every patient’s opportunity to live better, longer lives.
Discover the Improved Readability in ProFound AI Detection V3 Service Pack.
Radiologists Asked. We Delivered.
New features help breast imaging professionals quickly identify suspicious lesions by limiting the number of marks on each 3D view, and understand the level of suspicion related to lesions and the case through color-coded scoring ranges.
Improved Readability on Workstation:
• Limited number of marks
• Color-coded lesion marks
• Color-coded scorecard
Introducing iCAD’s AI Platform
ProFound Breast Health Suite
Powered by the latest innovations in artificial intelligence (AI), the ProFound Suite offers clinically proven, 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation. With about 2x improvement in clinical performance compared to other AI platforms,1 ProFound offers unrivaled accuracy, as well as multi‐vendor compatibility and unique workflow advantages.
Joining forces against a common enemy.
In the fight against cancer, we’re stronger together. Learn why our customers believe that our solutions are the secret weapon for cancer detection and treatment.
“Our retrospective study shows that AI has the potential to correctly identify a third of DBT screening exams as having no malignancy or an extremely low likelihood of malignancy. This AI-triaging could help radiologists determine which cases may need more intensive analysis”.
Emily F. Conant
Professor of Radiology and Vice Chair of Faculty Development in the Department of Radiology at the University of Pennsylvania, Perelman School of Medicine
“ProFound AI is a game-changer, helping us more confidently and efficiently move through cases, and with more accuracy than ever before. Whether recommending a biopsy or confidently dismissing a case, ProFound AI empowers our team with crucial insights that aid in clinical decisions”.
LAURA H. DEAN, MD
Radiologist, Section of Breast Imaging, Cleveland Clinic
“ProFound AI has provided a great deal of assistance in mammography decisions. ProFound AI uses artificial intelligence to rapidly and accurately analyze patients’ digital breast tomosynthesis images, producing a unique and quantifiable Certainty of Finding score for the patients’ overall case”.
KATHY SCHILLING, MD
Radiologist, Boca Raton Regional Hospital
Patient-Driven, AI-Powered
Creating a World Where Cancer Can’t Hide.
Implementation made easy.
Streamlining mammography workflows to create efficiencies and peace of mind.
With thousands of installations worldwide, our solutions offer multi-vendor compatibility that seamlessly integrate into the diagnostic process, in any reading environment.
Flexible turnkey solutions and service options designed to meet your unique deployment needs
ProFound Cloud
Connect via your private cloud, AI-marketplace, or directly with iCAD’s native cloud and support plans.
ProFound On-Premises
Onsite hardware conveniently pre-loaded with iCAD software plus warranty and service plans.
Interoperability: 50+ PACS & 94 versions | 2D & 3D OEM manufacturers | AI platform providers & workflow systems
Reserve time in-person or virtually.
We look forward to meeting with you.
Let us show you our suite of clinically proven AI-powered breast cancer detection, density assessment, and risk evaluation solutions provide certainty and peace of mind, improving patient outcomes and saving lives.
Disclaimer:
• ProFound AI (new 4th generation) is pending CE Mark, Health Canada, and FDA Clearance.
• ProFound AI Risk is CE Marked, Health Canada Licensed, and available for investigational use only in the U.S.
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed 1-20-23. FDA 510K submissions K182373 (iCAD), K201019 (Hologic) and K193229 (ScreenPoint).
- https://www.nationalbreastcancer.org/early-detection-of-breast-cancer. Accessed 11-01-2023